Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non-small Cell Lung Cancer

Next Previous
X
Search
Trial Profile

Phase 0/1 Study of the Safety and Tolerability of 177Lu-RAD204, a Lutetium-177 Radiolabelled Single Domain Antibody Against Programmed Cell Death-Ligand 1 in Patients with Metastatic Non-small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RAD 204 (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
  • Sponsors Radiopharm Theranostics

    • Most Recent Events

    • 21 May 2024 Planned initiation date (estimated date of first participant enrollment) changed from 1 Mar 2024 to 1 May 2024.
    • 10 Oct 2023 New trial record
    • 09 Oct 2023 According to Radiopharm theranostics media release, the company announce it has been granted Human Research Ethics Committee (HREC) approval to commence this trial; The study will be conducted at Princess Alexandra Hospital in Brisbane, Australia, with the support of leading oncology care provider GenesisCare; the trial is expected to start shortly

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top